Drug General Information |
Drug ID |
D0Y7NV
|
Former ID |
DNC003987
|
Drug Name |
5-Biphenyl-4-yl-5-ethyl-pyrimidine-2,4,6-trione
|
Drug Type |
Small molecular drug
|
Indication |
Discovery agent
|
Investigative |
[1]
|
Structure |
|
Download
2D MOL
3D MOL
|
Formula |
C18H16N2O3
|
Canonical SMILES |
CCC1(C(=O)NC(=O)NC1=O)C2=CC=C(C=C2)C3=CC=CC=C3
|
InChI |
1S/C18H16N2O3/c1-2-18(15(21)19-17(23)20-16(18)22)14-10-8-13(9-11-14)12-6-4-3-5-7-12/h3-11H,2H2,1H3,(H2,19,20,21,22,23)
|
InChIKey |
XWZIZWWEAJZAMO-UHFFFAOYSA-N
|
PubChem Compound ID |
|
Target and Pathway |
Target(s) |
MMP-9 |
Target Info |
Inhibitor |
[1]
|
Stromelysin-1 |
Target Info |
Inhibitor |
[1]
|
72 kDa type IV collagenase |
Target Info |
Inhibitor |
[1]
|
KEGG Pathway
|
TNF signaling pathway
|
Leukocyte transendothelial migration
|
Estrogen signaling pathway
|
Hepatitis B
|
Pathways in cancer
|
Transcriptional misregulation in cancer
|
Proteoglycans in cancer
|
MicroRNAs in cancer
|
Bladder cancerhsa04668:TNF signaling pathway
|
Rheumatoid arthritishsa04670:Leukocyte transendothelial migration
|
GnRH signaling pathway
|
Bladder cancer
|
NetPath Pathway
|
ID Signaling Pathway
|
TWEAK Signaling Pathway
|
Leptin Signaling Pathway
|
TNFalpha Signaling PathwayNetPath_13:IL1 Signaling Pathway
|
IL4 Signaling PathwayNetPath_22:Leptin Signaling Pathway
|
TCR Signaling Pathway
|
PANTHER Pathway
|
Alzheimer disease-presenilin pathway
|
Plasminogen activating cascade
|
CCKR signaling map STP00050:Plasminogen activating cascade
|
CCKR signaling map STP00004:Alzheimer disease-presenilin pathway
|
Pathway Interaction Database
|
LPA receptor mediated events
|
Plasma membrane estrogen receptor signaling
|
Osteopontin-mediated events
|
Validated transcriptional targets of AP1 family members Fra1 and Fra2
|
Validated targets of C-MYC transcriptional activation
|
CXCR4-mediated signaling events
|
amb2 Integrin signaling
|
Syndecan-4-mediated signaling events
|
AP-1 transcription factor network
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
|
Syndecan-1-mediated signaling events
|
Regulation of nuclear beta catenin signaling and target gene transcription
|
FGF signaling pathwayajdiss_2pathway:Posttranslational regulation of adherens junction stability and dissassembly
|
p75(NTR)-mediated signaling
|
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signalinglysophospholipid_pathway:LPA receptor mediated events
|
Angiopoietin receptor Tie2-mediated signaling
|
Direct p53 effectors
|
ATF-2 transcription factor network
|
FOXM1 transcription factor network
|
Syndecan-2-mediated signaling events
|
Reactome
|
Collagen degradation
|
Degradation of the extracellular matrix
|
Activation of Matrix Metalloproteinases
|
Assembly of collagen fibrils and other multimeric structures
|
EPH-ephrin mediated repulsion of cellsR-HSA-1442490:Collagen degradation
|
EGFR Transactivation by GastrinR-HSA-1442490:Collagen degradation
|
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
|
EPH-ephrin mediated repulsion of cells
|
WikiPathways
|
Endochondral Ossification
|
IL1 and megakaryotyces in obesity
|
Mammary gland development pathway - Involution (Stage 4 of 4)
|
Activation of Matrix Metalloproteinases
|
Degradation of collagen
|
Spinal Cord Injury
|
AGE/RAGE pathway
|
TWEAK Signaling Pathway
|
Angiogenesis
|
Osteopontin Signaling
|
Matrix MetalloproteinasesWP2769:Activation of Matrix Metalloproteinases
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
Oncostatin M Signaling Pathway
|
Matrix Metalloproteinases
|
References |
REF 1 | Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors. |